Urology Times staff

“We think given the accuracy that this is potentially a game changer,” says Laurence Klotz, MD, FRCSC.

“More research needs to be done, but I think this is something that gets the conversation started,” says Tony Chen, MD.

“The take-home message for all practicing urologists should be that if you have an nmCRPC patient, don't wait for them to develop mCRPC based on conventional imaging…We have 3 really efficacious level 1 evidence studies that have demonstrated the value for starting any of these 3 drugs,” says Neal D. Shore, MD.

“In those resistance cells, there is a lot of senescence occurring there, so that provides some potential target…which can be used to improve those PARP inhibitor therapies,” says Allen C. Gao, MD, PhD.

"In the clinic, I think the biggest benefit, at least immediately, is that by asking and trying to figure out what a patient's tobacco use history is, you can help with quitting,” says Richard Matulewicz, MD, MS.

"This particular study comes from our human randomized trial that we hope will be the final step before FDA approval for the technology,” says Mathew D. Sorensen, MD, MS, FACS.

“We have the rising spectra of national and international antibiotic resistance, which is becoming a huge international medical issue,” says J. Curtis Nickel, MD.

“We need to do a better job sampling the prostate,” says Matthew J. Allaway, MD.

“Although [whole-gland] treatments are very successful, from the oncologic perspective, our goal was to develop and test a new treatment modality in which we treat only the area with the significant cancer using focused ultrasound in the MRI gantry,” says Behfar Ehdaie, MD, MPH.

“BCG-unresponsive non–muscle-invasive bladder cancer is really [an] evolving space with a lot of uncertainty,” says Kelly L. Stratton, MD.

“Patients want to see an improvement. They want a drug that obviously is efficacious and safe, where the side effects are low,” says David Staskin, MD.

“What was very impressive from the study was by sequentially using Cxbladder Triage, Detect, and Resolve, we could not only segregate those who had cancer versus not, but also those who had low-risk tumors versus high-risk tumors,” says Jay Raman, MD, FACS.

“[These patients] have very limited treatment options and the adult muscle derived cells for sphincter regeneration represent a non-surgical means to provide very durable and effective support for these women who have suffered mightily from stress incontinence, oftentimes for long periods of time,” says Melissa R. Kaufman, MD, PhD, FACS.

“We believed that the drug would work as well in OAB wet as [it did] in OAB dry, so we're pleased to see that it was statistically significantly better than placebo at the 12 week point for looking at response to those metrics,” says David Staskin, MD.

“The Zenflow device is certainly something that…appears to be able to be placed quite easily, seems to be minimally invasive [and] so far seems to be durable,” says Peter Chin, MD.

“I think the real driving factor in all of this is that collecting smoking status and tobacco use is hard. It's difficult to get this information out. It requires a lot of time; it requires energy; it requires infrastructure in the data and the electronic medical record,” says Richard Matulewicz, MD, MS.

“The reason that [long-term follow up is] important is because if you look at the best of hands, the incidence of recurrence of upper tract urothelial carcinoma, even for low and intermediate risk, is still very high,” says Karim Chamie, MD.

“My patient selection process for BPH treatments can be a little bit cumbersome and take time, but that's really because for the first time ever, we have so many different options available to men,” says Dean Elterman, MD, MSc, FRCSC.

“We [found] that patients' overall [total] bowel symptoms scores were improved for those of the patients who received the active therapeutic treatment of [darolutamide] versus placebo,” says Neal D. Shore, MD, FACS.

“The purpose of [Cxbladder] Resolve is to identify not only those patients who are at higher risk for urothelial or urinary tract cancer, but those that have a high probability of an aggressive cancer, such as high-grade TA, carcinoma in situ, or T1 to T3,” says Jay Raman, MD, FACS.

“The most important takeaway is really good preoperative counseling. Patients should not expect surgeries to be pain free,” says Sarah F. Faris, MD.

“We're not saying a blanket stop for all patients, but I think we do need to be taking each patient as an individual in terms of their backgrounds,” says Jai Seth, MD.

“The notable finding was that the combination was well tolerated,” says Kelly L. Stratton, MD.

“This technology is truly a transformational opportunity for urology,” says Melissa R. Kaufman, MD, PhD, FACS.

“I think Aquablation is safe. It’s efficacious, especially in these large prostates,” says Kevin Zorn, MD, FRCSC, FACS.

“For some men, it's very important to make sure that they have an antegrade ejaculation and this is a treatment modality that we're able to offer them,” says Andrew Higgins, MD.

“What's novel about the iTind system is [that] it's one of the first treatments that [can] be deployed through a flexible cystoscope, as well as the fact that there is no permanent energy or permanent foreign body that's left within the prosthetic urethra,” says Bilal Chughtai, MD.

“This device is unique in that because it's done during real-time MRI imaging while the patient is in the MRI machine, [we] can monitor the temperatures achieved by our treatment in real time and make adjustments in real time. What that means is that we're able to determine areas that will be sensitive to the treatment, both cancer and areas from a quality-of-life perspective,” says Behfar Ehdaie, MD.

“We need to treat our patients with stones, both medically and surgically,” says Glenn M. Preminger, MD.

“This is the beginning of an exploration and an identification,” says Steven A. Kaplan, MD.